Proteasome Inhibition Improves the Muscle of Laminin {alpha}2 Chain Deficient Mice.

Virginie Carmignac, Ronan Quere, Madeleine Durbeej-Hjalt

Research output: Contribution to journalArticlepeer-review

51 Citations (SciVal)


Muscle atrophy, a significant characteristic of congenital muscular dystrophy with laminin α2 chain deficiency (also known as MDC1A), occurs by a change in the normal balance between protein synthesis and protein degradation. The ubiquitin-proteasome system plays a key role in protein degradation in skeletal muscle cells. In order to identify new targets for drug therapy against MDC1A, we have investigated whether increased proteasomal degradation is a feature of MDC1A. Using the generated dy(3K)/dy(3K) mutant mouse model of MDC1A, we studied the expression of members of the ubiquitin-proteasome pathway in laminin α2 chain deficient muscle and we treated dy(3K)/dy(3K) mice with the proteasome inhibitor MG-132. We show that members of the ubiquitin-proteasome system are upregulated and that the global ubiquitination of proteins is raised in dystrophic limb muscles. Also, phosphorylation of Akt is diminished in diseased muscles. Importantly, proteasome inhibition significantly improves the dystrophic dy(3K)/dy(3K) phenotype. Specifically, treatment with MG-132 increases lifespan, enhances locomotive activity, enlarges muscle fiber diameter, reduces fibrosis, restores Akt phosphorylation and decreases apoptosis. These studies promote better understanding of the disease process in mice and could lead to a drug therapy for MDC1A patients.
Original languageEnglish
Pages (from-to)541-552
JournalHuman Molecular Genetics
Issue number3
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Medical Genetics


Dive into the research topics of 'Proteasome Inhibition Improves the Muscle of Laminin {alpha}2 Chain Deficient Mice.'. Together they form a unique fingerprint.

Cite this